Clinical trial of rexlemestrocel-L (MPC-150-IM mesenchymal stem cells) in patients with NYHA class IV heart failure.

Trial Profile

Clinical trial of rexlemestrocel-L (MPC-150-IM mesenchymal stem cells) in patients with NYHA class IV heart failure.

Recruiting
Phase of Trial: Phase III

Latest Information Update: 14 Jun 2016

At a glance

  • Drugs Rexlemestrocel-L (Primary)
  • Indications Heart failure
  • Focus Registrational; Therapeutic Use
  • Most Recent Events

    • 14 Jun 2016 According to a MESOBLAST media release, results from this trial are expected in the second half of 2017 and will be used to support marketing approval application for rexlemestrocel-L
    • 14 Jun 2016 According to a MESOBLAST media release, this trial is close to 60% recruited.
    • 25 Nov 2014 The National Institutes of Health has agreed to fund this trial, according to a Mesoblast media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top